experimental group, received a supplement of oats beta-glucan (5 g) for 12 weeks.

placebo group, received a supplement of cellulose microcrystalline (5g) for 12 weeks.

Type2 Diabetes

44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.

Oat Beta-glucan as a Supplement in Type 2 Diabetics

Centro de Estudios en Alimentación y Nutrición

Oat Beta-glucan as a Supplement in Chilean Type 2 Diabetics

Oat β-glucans as a Supplement in Chilean Subjects With Type 2 Diabetes for Metabolic Control

José Luis Pino Villalón

Nutritionist

Centro de Estudios en Alimentación y Nutrición, Chile

Two groups were used: experimental (n 17): they received oat beta-glucan supplement to be added to breakfast (5 g). Control group: they received a placebo supplement (microcrystalline cellulose). Both groups received a container with the product and a dosing measure (5 g). The intervention was developed for 12 weeks. Blood samples and stools were taken at the beginning and end of the intervention.

One intradermal injection of 0.1ml of sodium chloride 0.9%

One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)

Infection

Hospitalization

Mortality

Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine

Vaccination

Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%

Placebo

4th Department of Internal Medicine, ATTIKON University Hospital

Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly

A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly

The time interval to the first infection post hospital discharge between the two groups of treatment.

The rate of hospitalizations will be compared between the two groups of treatment

The time to first infection or sepsis episode will be compared between the two groups of treatment

The total number of infections will be compared between the two groups of treatment

The time to first hospitalization will be compared between the two groups of treatment

The number of antibiotic administrations will be compared between the two groups of treatment

Mortality will be compared between the two groups of treatment

Cytokine stimulation from peripheral blood monuclear cells will be compared between the two groups of treatment

Epigenetic changes of circulating monocytes will be compared between the two groups of treatment

The effect of BCG vaccination on cost of treatment for infections will be compared between the two groups of treatment

1 3 glucan/necrosis

Oat Beta-glucan as a Supplement in Chilean Type 2 Diabetics

Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly

Baz done ki pi konplè remèd fèy medsin te apiye nan syans